Amylin inks diabetes pact with Biocon

San Diego-based Amylin Pharmaceuticals plans to join forces with India's Biocon to develop a new therapy for diabetes. The deal combines Amylin's expertise with hybrid molecules with Biocon's prowess in manufacturing and development. The deal can "unleash the potential of cutting-edge peptide science to transform the lives of patients with diabetes," says Amylin CEO Dan Bradbury. Report 

Suggested Articles

Half of patients in an early trial of Allogene's off-the-shelf CAR-T cells for lymphoma who received a higher dose of its antibody ALLO-647 responded.

Takeda is tossing out a Shire pipeline med after it couldn't find a buyer.

Ipsen's new hire arrives at a company reeling from a torrent six months that have crushed hopes for its $1 billion bet on a rare disease drug.